Ebselen

Drug Profile

Ebselen

Alternative Names: SPI-1005; SPI-3005

Latest Information Update: 14 Oct 2016

Price : $50

At a glance

  • Originator Nattermann
  • Developer Daiichi Sankyo Company; Nattermann; Sound Pharmaceuticals
  • Class Antiulcers; Azoles; Neuroprotectants; Nonsteroidal anti-inflammatories; Organoselenium compounds; Small molecules
  • Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Glutathione peroxidase stimulants; Leukotriene B4 receptor antagonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hearing loss; Noise-induced hearing loss; Sensorineural hearing loss; Tinnitus
  • Phase I/II Meniere's disease
  • Discontinued Asthma; Atherosclerosis; Cerebral infarction; Myocardial ischaemia; Peptic ulcer; Rheumatic disorders

Most Recent Events

  • 14 Oct 2016 Sound Pharmaceuticals plans a phase II trial for Aminoglycoside-induced ototoxicity in USA (Sound Pharmaceuticals pipeline, October 2016)
  • 12 Jul 2016 Sound Pharmaceuticals plans a phase I/II trial for Chemotherapy-induced hearing loss in USA (NCT02819856)
  • 18 May 2016 Sound Pharmaceuticals plans a phase II trial for Noise-induced hearing loss in USA (NCT02779192)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top